Monitor broad domains of well-being beyond symptom reduction

The manuals converge on the idea that monitoring in psychedelic-related care extends beyond symptom reduction. Across the extracts, the sources recommend tracking broader domains such as mood, cognition, quality of life, spirituality, and other aspects of well-being, alongside more familiar psychiatric outcomes like anxiety and depression. They also share an interest in how changes after treatment affect recovery, functioning, and the need for further support. The manuals differ in emphasis and clinical context. The cancer follow-up source places the strongest focus on existential and spiritual distress, including hopelessness, demoralization, death anxiety, and whether life changes are positive or destabilising. The 5-MeO-DMT study is narrower and more observational, centring on cognition, mood, subjective well-being, and any unusual persistence of psychological effects after dosing. The ayahuasca and psychotherapy source sits between these, highlighting quality of life, spirituality, motivation, and treatment satisfaction as recovery-related factors linked to symptom change.